Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
— XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. — XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO® in Indonesia with approval expected in the second half of 2024. — XPOVIO® has been approved for health […]